- ePoster presentation
- Open Access
Development of dual inhibitors targeting DprE1 and AHAS for treatment of Mycobacterium tuberculosis infection
BMC Infectious Diseases volume 14, Article number: E24 (2014)
The emerging multidrug resistant (MDR) and extensively drug resistant (XDR) Mycobacterium tuberculosis (MTB) infection is increasing with greater complexity, estimated 220000-400000 tuberculosis cases emerged in 2011 globally. A number of lead compounds have been developed for treatment of MDR and XDR TB, but no new chemical entity has emerged for clinical use. Recently DprE1 and AHAS have been identified as promising drug targets.
The methodology involved in silico studies, synthesis and in vitro evaluation for inhibition of M. tuberculosis. In silico studies involved protein preparation for DprE1, AHAS, docking and analysis of docking results. Sixty two substituted (thiazolidine-2-yl amino) benzthiazolylphenylhydrazine carbothiamide derivatives were studied. In vitro evaluation was carried out by modified agar diffusion method.
About 62 compounds were synthesized based on molecular docking studies. In case of DprE1 maximum interactions were found with His132, Asn385, Gly133, Leu134, Leu363, Val365, whereas in case of AHAS maximum interactions were shown between Arg318, Gly138, Lys197, Trp516 and Phe147. All compounds were synthesized in satisfactory yield and structurally elucidated. The range of MIC was found between 40-80 mg/L with percentage inhibition in range of 80-95%.
Experimental results reveales that newly developed compounds exhibited promising antitubercular activity which can be further explored for development of potent drugs.
About this article
Cite this article
Chikhale, R.V., Pant, A.M., Menghani, S.S. et al. Development of dual inhibitors targeting DprE1 and AHAS for treatment of Mycobacterium tuberculosis infection. BMC Infect Dis 14, E24 (2014). https://doi.org/10.1186/1471-2334-14-S3-E24
- Mycobacterium Tuberculosis
- Molecular Docking
- Docking Study
- Tuberculosis Case